Edesa BiotechのROCE
Edesa BiotechのROCEは何ですか。
Edesa Biotech, Inc.のROCEは-241.62%です。
ROCEの定義は何ですか。
使用資本利益率(ROCE)は、企業の収益性とその資本が使用される効率を測定する財務比率です。
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
NASDAQのセクタHealth CareにおけるROCEの企業と比べるEdesa Biotech
Edesa Biotechは何をしますか。
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotechと類似のroce
- BioXcel Therapeutics IncのROCEは-245.99%です。
- Verrica Pharmaceuticals IncのROCEは-244.95%です。
- Shift TechnologiesのROCEは-244.72%です。
- Qumu CorpのROCEは-244.21%です。
- Bellerophon Therapeutics IncのROCEは-243.25%です。
- ChesapeakeのROCEは-242.92%です。
- Edesa BiotechのROCEは-241.62%です。
- VermillionのROCEは-241.19%です。
- LadRx CorpのROCEは-241.02%です。
- Mvp Hldgs Inc NewのROCEは-240.98%です。
- Stellar AfricaGoldのROCEは-240.24%です。
- BigDish PlcのROCEは-239.87%です。
- Titan Medical IncのROCEは-239.26%です。